Table 1

Clinical characteristics of patients receiving ACT as well as their cell dose, dominant Vβ-gene usage and short-term outcomes

PatientSubtypeAgePrior treatmentSites of active disease at time of study treatmentCell dose (×109)Dominant clone Vβ-geneClinical outcome
Cy1MRCL35A/I, RtxLung27.5TRBV5-4*01Stable disease, resected to NED. Progression 1 year after ECT
Cy2SS26A/ILung, liver20TRBV12-3*01Progression at 8–10 weeks despite initial 20% reduction in a liver lesion at 4 weeks
Cy3SS27Sorafenib, epirubicin, ifosfamide, RtxLung19.8TRBV4*-1*01Progression at 8–10 weeks, despite regression at 4 weeks post-ECT with 36% reduction in a lung lesion
Cy4MRCL62A/I, dacarbazine, gem/tax, sorafenib, capecitabine, erlotinib, pazopanibLung, mediastinum, abdomen/retroperitoneum (multiple sites), pelvis, bone19TRBV9*01Progression at 8–10 weeks, despite regression in some lesions including 16% reduction in a mediastinal lesion with improved pain
  • Prior lines of treatment and sites of disease are at the time of trial enrollment.

  • ACT, adoptive cellular therapy; ECT, electroconvulsive therapy; MRCL, myxoid/round cell liposarcoma; NED, no evidence of disease; PBMC, peripheral blood mononuclear cells; SS, synovial sarcoma.